跳至主要内容
临床试验/NL-OMON35031
NL-OMON35031已完成不适用

Cost-effectiveness of treatment strategies for intermittent claudication - Cost-effectiveness of treatment strategies for intermittent claudication

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 210 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
210

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Rutherford category 1, 2, or 3
  • 2. Maximum pain-free walking distance <350m
  • 3. ABI <0.9 at rest or ABI decreasing by >0.15 after the treadmill test;
  • 4. >=1 vascular stenoses of >50% diameter reduction at the iliac or femoro-popliteal level.
  • 5. Informed consent

排除标准

  • 1. Abdominal aortic aneurysm
  • 2. Life-incapacitating cardiac disease (NYHA classification III and higher);
  • 3. Multilevel disease (i.e., same-side stenoses at both the iliac and femoral levels, requiring multiple revascularization procedures)
  • 4. Isolated tibial artery disease
  • 5. Lesions deemed unsuitable for revascularization
  • 6. Prior treatment for the same lesion (including exercise training)

研究者

相似试验